Relmada Therapeutics to Join Goldman Sachs 45th Annual Global Healthcare Conference

CORAL GABLES, Fla., June 10, 2024 — Relmada Therapeutics (Nasdaq: RLMD), a late-stage biotechnology firm specializing in central nervous system (CNS) disorders, has announced that its CEO, Sergio Traversa, will be taking part in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference. This event will be held in Miami, Florida, on Wednesday, June 12, 2024, at 11:20am ET. Alongside this presentation, Relmada management will be available for one-on-one investor meetings.

Event Details:
- Conference: 2024 Goldman Sachs Annual Global Healthcare Conference
- Format: Fireside Chat
- Date: Wednesday, June 12, 2024
- Time: 11:20am ET

For those who cannot attend in person, the presentation will be webcast live, accessible through the Investors section of Relmada’s website. Additionally, an archived replay will be available for 90 days post-conference.

About REL-1017

REL-1017 is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that targets hyperactive channels while preserving normal glutamatergic neurotransmission. Currently, it is in late-stage development for the adjunctive treatment of major depressive disorder (MDD). The clinical research program includes two Phase 3 studies, Reliance II (Study 302) and Relight (Study 304), which share key design parameters. The goal is to establish REL-1017 as a rapid-acting, oral, once-daily antidepressant.

About Relmada Therapeutics, Inc.

Relmada Therapeutics focuses on developing treatments for CNS diseases, with a primary emphasis on major depressive disorder. The company’s lead program, REL-1017, aims to offer a novel approach to treating MDD by targeting specific NMDA receptor channels. The company’s team is dedicated to improving patient outcomes and advancing clinical research.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!